Apps News Health Apps Profiting From Copycat Weight Loss Drugs On Borrowed Time

Ozempic Maker Novo Nordisk Lowers Growth Outlook

Novo Nordisk NOVO.B1.57%increase; green up pointing triangle lowered its sales and profit guidance as the pharmaceutical company contends with intensifying competition, pricing pressure and copycat ... Read More

This era of weight loss drugs requires a new kind of health platform

The question now is how to best serve the millions who, freed from a lifetime of yo-yo dieting, are re-engaging with their health and looking for a helping hand. For many GLP-1 users, that success has ... Read More

How Novo Nordisk Is Trying to Regain Its Weight-Loss Edge

Danish drugmaker Novo Nordisk A/S was at the forefront of the weight-loss injection boom as people discovered that its Ozempic shot, originally developed to treat diabetes, could help trim their ... Read More

Are "twins" the key to weight loss apps' success?

As a person with an identical twin brother who consistently weighs less than I do, I can attest that -- without even really doing anything -- he can be a big motivator for weight loss for me. For ... Read More

Where the blockbuster weight loss drug market stands today — and what’s coming next

The blockbuster weight loss drug market is entering a new chapter of growth. Eli Lilly and Novo Nordisk are both focused on fighting for market share, ramping up supply, testing new uses for their ... Read More

Paying more for health insurance? Why weight-loss drugs may be driving up your premiums.

As open enrollment approaches, a variety of factors — including pricey GLP-1 weight-loss drugs — are poised to push already expensive premiums for employer-sponsored healthcare even higher in 2026, a ... Read More